Kurt Machemer
Overview
Kurt Machemer focuses his practice on meeting the business and legal needs of emerging growth companies in the life sciences and technology sectors, as well as venture capitalists and other investors in early-stage companies. He represents organizations at various stages of development, including companies with marketed pharmaceutical products, medical devices/diagnostics, and various innovative drug development programs.
Career & Education
- Attorney, AmLaw 200 firm
- Attorney, Boston-based firm
- University of Michigan, B.A.
- Boston University School of Law, J.D.
- Massachusetts
Kurt's Insights
Firm News | 1 min read | 02.17.26
Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership
Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies.
Client Alert | 3 min read | 01.07.26
Event | 10.25.25
Client Alert | 3 min read | 10.13.25
Representative Matters
Before joining Crowell Life Sciences in 2025, Kurt was Principal at Faber Daeufer & Itrato PC. In this capacity, he led numerous formations, equity financings, acquisitions, mergers and reverse mergers, and collaborations for a wide cross-section of clients in the life sciences ecosystem. Select representative matters during his time at Faber include:
- Formation and equity financing of an innovative antibody discovery biopharmaceutical company by multiple investment firms and venture capital partners
- Financings of Actithera by M Ventures and Arkin Bio-Holdings
- Acquisition of Proteros biostructures GmbH’s ownership stake in Rodin Therapeutics by Alkermes
- Equity financing of NextPoint Therapeutics by Leaps by Bayer, Sanofi Ventures, MPM Capital Management, Dana-Farber Cancer Institute, Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners
- Foundation for Angelman Syndrome Therapeutics (FAST) in its venture with Couragene, Inc. to create CourageAS, Inc.
- Equity financing of Rila Therapeutics
- Praeventix in connection with a private investment by Tellus BioVentures
- In-license of foundational intellectual property from academia and equity financing of NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical
- Foundation for Angelman Syndrome Therapeutics’ (FAST) collaboration with the University of Pennsylvania
- Equity financing of Claris Biotherapeutics by Novo Ventures and others
- Equity investment by Novo A/S in ZS Pharma
Kurt's Insights
Firm News | 1 min read | 02.17.26
Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership
Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies.
Client Alert | 3 min read | 01.07.26
Event | 10.25.25
Client Alert | 3 min read | 10.13.25
Insights
Kurt's Insights
Firm News | 1 min read | 02.17.26
Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership
Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies.
Client Alert | 3 min read | 01.07.26
Event | 10.25.25
Client Alert | 3 min read | 10.13.25
